- Conditions
- Sickle Cell Disease
- Interventions
- Deferoxamine, Deferasirox, Deferiprone, Echocardiography, Electrocardiogram (ECG)
- Drug · Device
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Fairfax, Virginia • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced May 21, 2026, 10:51 PM EDT